Therapy-related core binding factor acute myeloid leukemia

Therapy-related acute myeloid leukemia (t-AML) usually stems from exposure of the bone marrow to cytotoxic chemotherapy and/or radiation therapy. t-AML is usually associated with poor overall survival, but occasionally t-AML can involve favorable-risk cytogenetics, including core binding factor AML...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Binsah, Yohannan, Binoy, Mohlere, Virginia, Gonzalez, Anneliese
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979104/
https://www.ncbi.nlm.nih.gov/pubmed/36874378
http://dx.doi.org/10.2217/ijh-2022-0004
Descripción
Sumario:Therapy-related acute myeloid leukemia (t-AML) usually stems from exposure of the bone marrow to cytotoxic chemotherapy and/or radiation therapy. t-AML is usually associated with poor overall survival, but occasionally t-AML can involve favorable-risk cytogenetics, including core binding factor AML (CBF-AML), which shows a recurrent chromosomal rearrangement with t(8;21) (q22;22) and ‘inv(16) (p13.1;q22)/t(16;16)(p13.1;q22)’, leading to ‘RUNX1::RUNX1T1 and CBFB::MYH11’ fusion genes, respectively. Therapy-related CBF-AML (t-CBF-AML) accounts for 5–15% of CBF-AML cases and tends to have better outcomes than t-AML with unfavorable cytogenetics. Although CBF-AML is sensitive to high-dose cytarabine, t-CBF-AML has worse overall survival than de novo CBF- AML. The objective of this review is to discuss the available data on the pathogenesis, mutations, and therapeutic options in patients with t-CBF-AML.

Ejemplares similares